[클리니컬 히스토리] JW신약, 모발관리 데이터 공개…상업화 근거 강화

JW Shinyak is strategically pivoting from a prescription-only hair loss drug model to a broader portfolio including dermocosmetics to offset the declining sales of its flagship drug, Monad. By securing clinical data for Ducray Neoptide Expert, the company aims to leverage its clinic-based distribution network and capture the growing hair management market. This transition highlights a broader industry trend where pharmaceutical firms diversify into consumer healthcare to overcome core business stagnation.